Fractyl Health (GUTS) Cash from Financing Activities (2023 - 2026)
Fractyl Health (GUTS) reported Cash from Financing Activities of $4.1 million for Q1 2026, up 2300.58% year-on-year from $171000.0 in Q1 2025, and down 83.72% quarter-over-quarter from $25.2 million in Q4 2025.
Fractyl Health (GUTS) has 4 years of Cash from Financing Activities data on file, last reported at $4.1 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 2300.58% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $108.9 million (up 27468.35% YoY), and the FY2025 full-year result was $105.0 million, up 3.69% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $4.1 million, down from $25.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $101.0 million in Q1 2024 and bottomed at -$556000.0 in Q4 2023.
- A 4-year average of $18.3 million and a median of $171000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 5050200.0% in 2024, while the deepest fall reached 117.86% in 2024.
- Tracing GUTS's Cash from Financing Activities over 4 years: stood at -$556000.0 in 2023, then jumped by 112.05% to $67000.0 in 2024, then jumped by 37544.78% to $25.2 million in 2025, then slumped by 83.72% to $4.1 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $4.1 million, $25.2 million, and $78.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | 4.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.11 Mn |
| Mar 31, 2026 | 4.11 Mn |
| Dec 31, 2025 | 25.22 Mn |
| Dec 31, 2025 | 25.22 Mn |
| Sep 30, 2025 | 78.09 Mn |
| Sep 30, 2025 | 78.09 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 171,000.00 |
| Mar 31, 2025 | 171,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | 101.00 Mn |
| Mar 31, 2024 | 101.00 Mn |
| Dec 31, 2023 | -556,000.00 |
| Dec 31, 2023 | -556,000.00 |
| Sep 30, 2023 | 27.97 Mn |
| Sep 30, 2023 | 27.97 Mn |
| Jun 30, 2023 | 28,000.00 |
| Jun 30, 2023 | 28,000.00 |
| Mar 31, 2023 | -2,000.00 |
| Mar 31, 2023 | -2,000.00 |